DOV Pharmaceutical, Inc. (OTCBB: DOVP) announced that it has initiated a Phase II clinical trial of DOV 21,947 in patients diagnosed with major depressive disorder. DOV 21,947 is DOV’s lead triple reuptake inhibitor, or “TRIP,” for the treatment of depression and obesity. The clinical trial, which will randomize approximately 200 patients, is a double-blind, placebo-controlled, multi-center study assessing the efficacy and safety of DOV 21,947 over a six-week period.
Popularity: unranked [?]
Related posts:
- Targacept’s TC-5214 Achieves All Primary And Secondary Outcome Measures In Phase 2b Trial As Augmentation Treatment For Major Depressive Disorder
- Clinical Data, Inc. Initiates Second Pivotal Phase III Study Of Vilazodone
- Targacept Announces Positive Results Of Phase II Clinical Trial In Major Depression
- Swedish Rhodiola Rosea Extract Effective In Treating Mild To Moderate Depression In New Clinical Trial
- Swedish Rhodiola Rosea Extract Effective In Treating Mild To Moderate Depression In New Clinical Trial
Comments
No Responses to “DOV Pharmaceutical, Inc. Initiates Phase II Clinical Trial In Patients With Major Depressive Disorder”